A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel

80Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

Abstract

Background: Preclinical and early phase clinical microbicide studies have not consistently predicted the outcome of efficacy trials. To address this gap, candidate biomarkers of microbicide pharmacodynamics and safety were evaluated in a doubleblind, placebo-controlled trial of tenofovir gel, the first microbicide to demonstrate significant protection against HIV acquisition. Methods: 30 women were randomized to apply a single daily dose of tenofovir or placebo gel for 14 consecutive days. Anti- HIV activity was measured in cervicovaginal lavage (CVL) on Days 0, 3, 7, 14 and 21 by luciferase assay as a surrogate marker of pharmacodynamics. Endogenous activity against E. coli and HSV-2 and concentrations of immune mediators were quantified in CVL as candidate biomarkers of safety. Tenofovir levels were measured in CVL and blood. Results: A significant increase in anti-HIV activity was detected in CVL from women who applied tenofovir gel compared to their endogenous anti-HIV activity in genital tract secretions on Day 0 and compared to activity in CVL from women in the placebo group. The activity correlated significantly with CVL concentration of tenofovir (r = 0.6, p<0.001) and fit a sigmoid Emax pharmacodynamic model. Anti-HIV activity in CVL from women who applied tenofovir persisted when virus was introduced in semen, whereas endogenous anti-HIV activity decreased. Tenofovir did not trigger an inflammatory response or induce sustained loss in endogenous antimicrobial activity or immune mediators. Conclusions: Tenofovir gel had no deleterious impact on soluble mucosal immunity. The increased anti-HIV activity in CVL, which persisted in the presence of semen and correlated with tenofovir concentration, is consistent with the efficacy observed in a recent clinical trial. These results promote quantified CVL anti-HIV activity as a surrogate of tissue pharmacodynamics and as a potential biomarker of adherence to product. This simple, feasible and inexpensive bioassay may promote the development of models more predictive of microbicide efficacy.

Figures

  • Figure 1. Trial profile.
  • Table 1. Demographic data of recipients of 1% tenofovir and placebo gel.
  • Figure 2. Increased anti-HIV activity in CVL from women who applied tenofovir gel. Results are presented as mean percentage inhibition 6 SE obtained from two independent experiments, each conducted in triplicate. doi:10.1371/journal.pone.0016475.g002
  • Figure 3. Anti-HIV activity of TFV persists if virus is introduced in semen. TZM-bl cells were treated with CVL collected from four subjects in the TFV group (T) and 4 from the placebo group (P) on Day 7 and then challenged with HIV-1BaL diluted in medium alone or in medium containing 25% pooled whole human semen. Results are presented as mean percentage inhibition 6 SE obtained from two or three independent experiments, each conducted in triplicate. doi:10.1371/journal.pone.0016475.g003
  • Table 2. Blue Dye staining of polypropylene applicators.
  • Figure 4. CVL tenofovir levels correlate with anti-HIV activity in CVL. The concentration of TFV was determined in CVL samples collected on Days 3, 7, 14 and 21 (upper panel). Each data point represents the TFV level obtained from a single CVL sample, with the median for each group represented by a horizontal line. CVL TFV concentrations correlated positively and significantly with percentage inhibition of HIV (lower panel). doi:10.1371/journal.pone.0016475.g004
  • Figure 5. Endogenous anti-E. coli and anti-HSV activity following vaginal application of TFV and placebo gel. The percentage inhibition of E. coli was determined relative to colonies formed on control plates treated with GTB (upper panel). Vero cells were infected with HSV-2(G) mixed 1:1 with CVL or control buffer (lower panel). Results are presented as mean percentage inhibition of cfu or plaque forming units (pfu) 6 SE. All samples were tested in duplicate in two independent experiments. doi:10.1371/journal.pone.0016475.g005
  • Table 3. Summary of Day 0 concentrations of soluble immune mediators and pH and comparison of changes in levels between TFV and placebo groups.

References Powered by Scopus

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

2097Citations
N/AReaders
Get full text

Glycerol monolaurate prevents mucosal SIV transmission

538Citations
N/AReaders
Get full text

Targeting early infection to prevent HIV-1 mucosal transmission

504Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men

812Citations
N/AReaders
Get full text

HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention

280Citations
N/AReaders
Get full text

MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments

168Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Keller, M. J., Madan, R. P., Merna Torres, N., Fazzari, M. J., Cho, S., Kalyoussef, S., … Herold, B. C. (2011). A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS ONE, 6(1). https://doi.org/10.1371/journal.pone.0016475

Readers over time

‘11‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘240481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

47%

Researcher 15

42%

Professor / Associate Prof. 4

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 21

66%

Agricultural and Biological Sciences 5

16%

Pharmacology, Toxicology and Pharmaceut... 3

9%

Biochemistry, Genetics and Molecular Bi... 3

9%

Save time finding and organizing research with Mendeley

Sign up for free
0